{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:37:59Z","timestamp":1788730679653,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Does the addition of oral dydrogesterone to vaginal progesterone as luteal phase support improve pregnancy outcomes during frozen embryo transfer (FET) cycles compared with vaginal progesterone alone?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Luteal phase support with oral dydrogesterone added to vaginal progesterone had a higher live birth rate and lower miscarriage rate compared with vaginal progesterone alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Progesterone is an important hormone that triggers secretory transformation of the endometrium to allow implantation of the embryo. During IVF, exogenous progesterone is administered for luteal phase support. However, there is wide inter-individual variation in absorption of progesterone via the vaginal wall. Oral dydrogesterone is effective and well tolerated when used to provide luteal phase support after fresh embryo transfer. However, there are currently no data on the effectiveness of luteal phase support with the combination of dydrogesterone with vaginal micronized progesterone compared with vaginal micronized progesterone after FET.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>Prospective cohort study conducted at an academic infertility center in Vietnam from 26 June 2019 to 30 March 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>We studied 1364 women undergoing IVF with FET. Luteal support was started when endometrial thickness reached \u22658\u2009mm. The luteal support regimen was either vaginal micronized progesterone 400\u2009mg twice daily plus oral dydrogesterone 10\u2009mg twice daily (second part of the study) or vaginal micronized progesterone 400\u2009mg twice daily (first 4\u2009months of the study). In women with a positive pregnancy test, the appropriate luteal phase support regimen was continued until 7 weeks\u2019 gestation. The primary endpoint was live birth after the first FET of the started cycle, with miscarriage &amp;lt;12\u2009weeks as one of the secondary endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>The vaginal progesterone + dydrogesterone group and vaginal progesterone groups included 732 and 632 participants, respectively. Live birth rates were 46.3% versus 41.3%, respectively (rate ratio [RR] 1.12, 95% CI 0.99\u20131.27, P\u2009=\u20090.06; multivariate analysis RR 1.30 (95% CI 1.01\u20131.68), P\u2009=\u20090.042), with a statistically significant lower rate of miscarriage at &amp;lt;12\u2009weeks in the progesterone + dydrogesterone versus progesterone group (3.4% versus 6.6%; RR 0.51, 95% CI 0.32\u20130.83; P\u2009=\u20090.009). Birth weight of both singletons (2971.0\u2009\u00b1\u2009628.4 versus 3118.8\u2009\u00b1\u2009559.2\u2009g; P\u2009=\u20090.004) and twins (2175.5\u2009\u00b1\u2009494.8 versus 2494.2\u2009\u00b1\u2009584.7; P\u2009=\u20090.002) was significantly lower in the progesterone plus dydrogesterone versus progesterone group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The main limitations of the study were the open-label design and the non-randomized nature of the sequential administration of study treatments. However, our systematic comparison of the two strategies was able to be performed much more rapidly than a conventional randomized controlled trial. In addition, the single ethnicity population limits external generalizability.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Our findings study suggest a role for oral dydrogesterone in addition to vaginal progesterone as luteal phase support in FET cycles to reduce the miscarriage rate and improve the live birth rate. Carefully planned prospective cohort studies with limited bias could be used as an alternative to randomized controlled clinical trials to inform clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTERESTS<\/jats:title>\n                  <jats:p>This study received no external funding. LNV has received speaker and conference fees from Merck, grant, speaker and conference fees from Merck Sharpe and Dohme, and speaker, conference and scientific board fees from Ferring; TMH has received speaker fees from Merck, Merck Sharp and Dohme, and Ferring; R.J.N. has received scientific board fees from Ferring and receives grant funding from the National Health and Medical Research Council (NHMRC) of Australia; BWM has acted as a paid consultant to Merck, ObsEva and Guerbet, and is the recipient of grant money from an NHMRC Investigator Grant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>NCT0399876.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deab093","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T11:45:16Z","timestamp":1617277516000},"page":"1821-1831","source":"Crossref","is-referenced-by-count":62,"title":["Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-6912","authenticated-orcid":false,"given":"Lan N","family":"Vuong","sequence":"first","affiliation":[{"name":"University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toan D","family":"Pham","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh T Q","family":"Le","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung T","family":"Ly","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-170X","authenticated-orcid":false,"given":"Ho L","family":"Le","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diem T N","family":"Nguyen","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-8393","authenticated-orcid":false,"given":"Vu N A","family":"Ho","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinh Q","family":"Dang","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan H","family":"Phung","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Norman","sequence":"additional","affiliation":[{"name":"Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben W","family":"Mol","sequence":"additional","affiliation":[{"name":"Monash University, Melbourne, Australia"},{"name":"Aberdeen Centre for Women's Health Research, School of Medicine, University of Aberdeen, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuong M","family":"Ho","sequence":"additional","affiliation":[{"name":"IVFMD, My Duc Hospital and HOPE Research Center, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"2021070807483289000_deab093-B1","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/humrep\/der037","article-title":"The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting","volume":"26","year":"2011","journal-title":"Hum Reprod"},{"key":"2021070807483289000_deab093-B2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc18-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"2021070807483289000_deab093-B3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0002-9378(95)90268-6","article-title":"Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone","volume":"173","author":"Archer","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"2021070807483289000_deab093-B4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/uog.15814","article-title":"Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Barbosa","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2021070807483289000_deab093-B5","doi-asserted-by":"crossref","first-page":"263.e261","DOI":"10.1016\/j.ajog.2019.06.019","article-title":"Pharmacokinetics of vaginal progesterone in pregnancy","volume":"221","author":"Boelig","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"2021070807483289000_deab093-B6","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.maturitas.2009.09.012","article-title":"Luteal support: progestogens for pregnancy protection","volume":"65","author":"Daya","year":"2009","journal-title":"Maturitas"},{"key":"2021070807483289000_deab093-B7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.fertnstert.2017.11.004","article-title":"Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial","volume":"109","author":"Devine","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807483289000_deab093-B8","doi-asserted-by":"crossref","first-page":"e0241044","DOI":"10.1371\/journal.pone.0241044","article-title":"Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: a systematic review and individual participant data meta-analysis","volume":"15","author":"Griesinger","year":"2020","journal-title":"PLoS One"},{"key":"2021070807483289000_deab093-B9","first-page":"2212","article-title":"Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial","volume":"33","author":"Griesinger","year":"2018","journal-title":"Hum Reprod"},{"key":"2021070807483289000_deab093-B10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.fertnstert.2018.03.034","article-title":"Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard?","volume":"109","author":"Griesinger","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807483289000_deab093-B11","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/DDDT.S210228","article-title":"Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2021070807483289000_deab093-B12","article-title":"Assessment of the immunomodulatory role of dydrogesterone in preventing pregnancy loss in threatened abortion","volume":"3","author":"Ibrahim","year":"2020","journal-title":"W J Gynecol Women\u2019s Health"},{"key":"2021070807483289000_deab093-B13","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/humrep\/dex316","article-title":"Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study","volume":"32","author":"Labarta","year":"2017","journal-title":"Hum Reprod"},{"key":"2021070807483289000_deab093-B14","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1210\/jc.2013-3937","article-title":"Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert","volume":"99","author":"Paulson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070807483289000_deab093-B15"},{"key":"2021070807483289000_deab093-B16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.apjr.2016.10.002","article-title":"Oral dydrogesterone for luteal support in frozen-thawed embryo transfer artificial cycles: a pilot randomized controlled trial","volume":"5","author":"Rashidi","year":"2016","journal-title":"Asian Pac J Reprod"},{"key":"2021070807483289000_deab093-B17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/humrep\/dex023","article-title":"A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization","volume":"32","author":"Tournaye","year":"2017","journal-title":"Hum Reprod"},{"key":"2021070807483289000_deab093-B18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.rbmo.2013.10.022","article-title":"Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey","volume":"28","author":"Vaisbuch","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"2021070807483289000_deab093-B19","first-page":"Cd009154","article-title":"Luteal phase support for assisted reproduction cycles","volume":"2015","author":"van der Linden","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070807483289000_deab093-B20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa1703768","article-title":"IVF transfer of fresh or frozen embryos in women without polycystic ovaries","volume":"378","author":"Vuong","year":"2018","journal-title":"N Engl J Med"},{"key":"2021070807483289000_deab093-B21","doi-asserted-by":"crossref","first-page":"e0133027","DOI":"10.1371\/journal.pone.0133027","article-title":"Crinone gel for luteal phase support in frozen-thawed embryo transfer cycles: a prospective randomized clinical trial in the Chinese population","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"2021070807483289000_deab093-B22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S0140-6736(18)32843-5","article-title":"Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial","volume":"393","author":"Wei","year":"2019","journal-title":"Lancet"},{"key":"2021070807483289000_deab093-B23","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.fertnstert.2010.02.033","article-title":"Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study","volume":"94","author":"Yanushpolsky","year":"2010","journal-title":"Fertil Steril"},{"key":"2021070807483289000_deab093-B24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.rbmo.2015.05.005","article-title":"Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement","volume":"31","author":"Yovich","year":"2015","journal-title":"Reprod Biomed Online"},{"key":"2021070807483289000_deab093-B25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00246-015-1190-9","article-title":"The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy","volume":"36","author":"Zaqout","year":"2015","journal-title":"Pediatr Cardiol"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/7\/1821\/38695676\/deab093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/7\/1821\/38695676\/deab093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T15:19:17Z","timestamp":1625757557000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/7\/1821\/6261149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,30]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab093","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,4,30]]}}}